AVENUE THERAPEUTICS ($ATXI) is expected to release its quarterly earnings data on Monday, March 17th after market close, per Finnhub. Analysts are expecting revenue ...

Avenue Therapeutics Inc (NASDAQ:ATXI) stock has tumbled to a 52-week low, touching down at $1.43, with a market capitalization of just $3.61 million. InvestingPro analysis shows the company ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Stay updated on market trends for ATXI. Avenue Therapeutics shares are trading lower by 20.7% during Monday's session. The company announced the exercise of warrants for $4.4 million in gross ...

Short interest in Avenue Therapeutics Inc (NASDAQ:ATXI) increased during the last reporting period, rising from 80.55K to 154.92K. This put 7.54% of the company's publicly available shares short.

Find the latest Avenue Therapeutics, Inc. ATXI analyst stock forecast, price target, and recommendation trends with in-depth analysis from research reports.

Avenue Therapeutics Inc . (NASDAQ:ATXI) stock has reached a new 52-week low, trading at $1.22, marking a significant downturn for the pharmaceutical company. With a market... ByInvesting.com • 5 ...

Enhance your stock picks with dividend metrics like per-share dividends, yield, frequency, payout ratios, and more.

Topline data in Phase 1b/2a clinical trial of AJ201 for spinal and bulbar muscular atrophy anticipated around year-end 2024MIAMI, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ...